In this video from OncLive, Director of the CLL Research Center, Richard R. Furman, M.D. discusses infusion reactions for chronic lymphocytic leukemia (CLL) patients treated with anti-CD20 antibodies, including rituximab, obinutuzumab, and ofatumumab.
Category: Patient Education
Dr. Richard Furman Discusses Recent Changes in CLL Treatment
In this video clip from OncLive, Director of the CLL Research Center, Richard R. Furman, M.D. discusses the new treatments that have changed the care for patients with chronic lymphocytic leukemia (CLL).
REDLAMP 8: Does a Geriatric Assessment Hold Prognostic Value for Patients with Aggressive NHL?
Diffuse large B-cell lymphoma is the most common non-Hodgkin lymphoma (NHL). It is an aggressive disease that often affects older patients.The journal Leukemia & Lymphoma, recently published a study investigating whether a geriatric assessment would be of prognostic value for patients with aggressive NHL. This included assessments of nutrition, frailty, cognitive ability, performance status, and relevant laboratory values. In this video, new faculty member, Dr. Sarah Rutherford explains the results of this study, and offers takeaways for older patients with aggressive NHL.
Previous #REDLAMP entries can be viewed on our Youtube channel.
We encourage you to follow the Lymphoma Program on Twitter, Youtube, and Facebook where we will highlight new videos are about research publications as they are released. We also welcome your feedback, suggestions and questions about this project. If you have other questions about our lymphoma program or clinical trials or would like to see one of our lymphoma specialists, please contact us at 646-962-2064.
New Developments in Lymphoma 